- Details
- Oliver Sartor presented the impact and use of radium-223 during the Bone and Bone Metastases Session at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Sartor explains how Radium-223 first gained prominence with the reporting of the ALSYMPCA trial in 2013 which led to the FDA approval of radium-223 in the United States for patients with bone mCRPC without visceral metastases hi...
|
- Details
- Chris Parker presents on the utilization of antiresorptive therapy to reduce skeletal-related events (SRE) risk in men with bone metastatic castration-resistant prostate cancer (mCRPC) at the Advanced Prostate Cancer Consensus Conference (APCCC 2019). Dr. Parker's presentation was part of a debate featured during the Bone and Bone Metastases Session. He summarized the evidence base in 2002 after t...
|
- Details
- Bertrand Tombal presented the use of antiresorptive therapy to reduce the risk of skeletal-related events (SRE) for the majority of men with castration-resistant prostate cancer (CRPC) and bone metastases. This presentation was part of the debate regarding how aggressive to be with bone-targeted therapy at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 biennial meeting. Dr. Tombal'...
|
- Details
- Fred Saad presented on bone and bone metastases at the Advanced Prostate Cancer Consensus Conference (APCCC) 2019 focusing on the prevention and treatment of osteoporosis. Given the relationship between ADT and bone loss, previous studies have established that ADT leads to increased fracture rates. Along with a proposed approached for men on ADT, Dr. Saad recommends the use of Fracture Risk Assess...
|
- Details
- Evan Yu and Alicia Morgans share in a discussion on where we are in understanding treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) and sequencing treatments after progression from nmCPRC to mCRPC. The conversation includes selecting and evaluating patients with mCRPC and how treatments are selected for these patients. Dr. Yu discusses the opportunities to individualize tr...
|
- Details
- Dan George concentrated on the patient experience in the treatment of metastatic castration-resistant prostate cancer (mCRPC). He described a typical treatment timeline where a new patient presents with elevated PSA is initially treated with androgen deprivation therapy (ADP) to reduce testosterone feeding tumor growth. While the patient may initially respond with a reduced PSA, it is most common...
|
- Details
- Charles Ryan, MD, and Fred Saad, MD have a clinical discussion on the full spectrum of castration-resistant prostate cancer (CRPC) from inception in both symptomatic vs asymptomatic patients from the evolution of abiraterone acetate and enzalutamide to the time point of integrating therapies earlier into CRPC. Dr. Saad discusses the development of prostate cancer and the optimal way for clinicians...
|
- Details
- Neal Shore and Oliver Sartor discuss the role of both alpha and beta radiopharmaceuticals that are on the horizon for treatment of bone metastases in prostate cancer. Dr. Sartor reviews the compelling data for the use radium-223 with respect to the improvement seen in overall survival along with additional alpha targeted agents that are on the horizon. He also discusses the role of the beta agents...
|
- Details
- Daniel George is joined by a multi-specialty group of experts to discuss the latest research on CRPC with bone metastases. The conversation details the mechanism of action of Radium-223 in prostate cancer, a review of the ALSYMPCA trial and the impact of the ERA-223 trial. Biographies: Daniel George, MD is Professor of Medicine and Surgery, Divisions of Medical Oncology and Urology in the Duke Uni...
|
- Details
- Neal Shore and Oliver Sartor have a conversation on bone-targeted agent therapies in prostate cancer, specifically focusing on the ALSYMPCA phase three trial; the design, findings, the addition of radium-223 and what this trial has led to today. They review a few other current ongoing trials including the PEACE III single arm trial and other current approaches in understanding combination therapie...
|
